SecBot SecBot
SECBOTREPLAY Home › Report › FMS

FMS · The District Court for the District of Columbia dismissed Fresenius…

Fresenius Kabi U · COURT-RULING filed Mar 29, 2026 at 20:00 ET

At the news

BEARISHIMPACT 6/10

COURT-RULING filed Mar 29, 2026 at 20:00 ET

The District Court for the District of Columbia dismissed Fresenius Kabi USA, LLC's lawsuit against the U.S. government, ruling that CMS's September 2024 decision denying reclassification of certain heparin bag products as noninnovator drugs was not final agency action under the Administrative Procedure Act. The court found the decision was contingent on Fresenius Kabi's response, which it submitted, thereby triggering ongoing agency review and making judicial review premature.

  • Fresenius Kabi sued CMS to reclassify four heparin bag products as noninnovator drugs to reduce Medicaid rebate obligations.
  • CMS denied the reclassification in September 2024 but allowed Fresenius Kabi 30 days to respond with additional information, stating the decision would be final only if no response was received.
  • Fresenius Kabi submitted a detailed response within 30 days, including a 30-page white paper challenging CMS's position.
  • The court ruled the CMS decision was not final agency action because the company responded, keeping the administrative process open and making judicial review premature.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access